Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Editorial overview: New proteins, cellular processes and intercellular interactions involved in antigen presentation.

Mintern JD, Villadangos JA.

Curr Opin Immunol. 2019 Jun;58:iii-iv. doi: 10.1016/j.coi.2019.06.003. No abstract available.

PMID:
31279358
2.

Downregulation of MHC Class I Expression by Influenza A and B Viruses.

Koutsakos M, McWilliam HEG, Aktepe TE, Fritzlar S, Illing PT, Mifsud NA, Purcell AW, Rockman S, Reading PC, Vivian JP, Rossjohn J, Brooks AG, Mackenzie JM, Mintern JD, Villadangos JA, Nguyen THO, Kedzierska K.

Front Immunol. 2019 May 29;10:1158. doi: 10.3389/fimmu.2019.01158. eCollection 2019.

3.

Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia.

Roquilly A, Torres A, Villadangos JA, Netea MG, Dickson R, Becher B, Asehnoune K.

Lancet Respir Med. 2019 Aug;7(8):710-720. doi: 10.1016/S2213-2600(19)30140-7. Epub 2019 Jun 7. Review.

PMID:
31182406
4.

MARCH ligases in immunity.

Liu H, Mintern JD, Villadangos JA.

Curr Opin Immunol. 2019 Jun;58:38-43. doi: 10.1016/j.coi.2019.03.001. Epub 2019 May 4. Review.

PMID:
31063934
5.

MARCH1-mediated ubiquitination of MHC II impacts the MHC I antigen presentation pathway.

Wilson KR, Liu H, Healey G, Vuong V, Ishido S, Herold MJ, Villadangos JA, Mintern JD.

PLoS One. 2018 Jul 12;13(7):e0200540. doi: 10.1371/journal.pone.0200540. eCollection 2018.

6.

MR1 antigen presentation to MAIT cells: new ligands, diverse pathways?

McWilliam HE, Villadangos JA.

Curr Opin Immunol. 2018 Jun;52:108-113. doi: 10.1016/j.coi.2018.04.022. Epub 2018 May 10. Review.

PMID:
29754112
7.

The MARCH family joins the antigen cross-presentation party.

Mintern JD, Villadangos JA.

Immunol Cell Biol. 2017 Oct;95(9):737-738. doi: 10.1038/icb.2017.58. Epub 2017 Aug 22. No abstract available.

PMID:
28829049
8.

Local Modulation of Antigen-Presenting Cell Development after Resolution of Pneumonia Induces Long-Term Susceptibility to Secondary Infections.

Roquilly A, McWilliam HEG, Jacqueline C, Tian Z, Cinotti R, Rimbert M, Wakim L, Caminschi I, Lahoud MH, Belz GT, Kallies A, Mintern JD, Asehnoune K, Villadangos JA.

Immunity. 2017 Jul 18;47(1):135-147.e5. doi: 10.1016/j.immuni.2017.06.021.

9.

How MR1 Presents a Pathogen Metabolic Signature to Mucosal-Associated Invariant T (MAIT) Cells.

McWilliam HEG, Villadangos JA.

Trends Immunol. 2017 Sep;38(9):679-689. doi: 10.1016/j.it.2017.06.005. Epub 2017 Jul 5. Review.

PMID:
28688841
10.

Reply to: "Differential expression of serpins may selectively license distinct granzyme B functions including antigen cross-presentation".

Mangan MS, Vega-Ramos J, Joeckel LT, Mitchell AJ, Rizzitelli A, Roediger B, Kaiserman D, Weninger WW, Villadangos JA, Bird PI.

Mol Immunol. 2017 Jul;87:327-328. doi: 10.1016/j.molimm.2017.03.005. Epub 2017 Apr 6. No abstract available.

PMID:
28390658
11.

Serpinb9 is a marker of antigen cross-presenting dendritic cells.

Mangan MS, Vega-Ramos J, Joeckel LT, Mitchell AJ, Rizzitelli A, Roediger B, Kaiserman D, Weninger WW, Villadangos JA, Bird PI.

Mol Immunol. 2017 Feb;82:50-56. doi: 10.1016/j.molimm.2016.12.011. Epub 2016 Dec 24.

PMID:
28024184
12.

DNA-based probes for flow cytometry analysis of endocytosis and recycling.

Dumont C, Czuba E, Chen M, Villadangos JA, Johnston AP, Mintern JD.

Traffic. 2017 Apr;18(4):242-249. doi: 10.1111/tra.12466. Epub 2017 Feb 7.

13.

Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes.

Macri C, Dumont C, Panozza S, Lahoud MH, Caminschi I, Villadangos JA, Johnston AP, Mintern JD.

Mol Immunol. 2017 Jan;81:143-150. doi: 10.1016/j.molimm.2016.12.010. Epub 2016 Dec 12.

PMID:
27978488
14.

Ubiquitin ligase MARCH 8 cooperates with CD83 to control surface MHC II expression in thymic epithelium and CD4 T cell selection.

Liu H, Jain R, Guan J, Vuong V, Ishido S, La Gruta NL, Gray DH, Villadangos JA, Mintern JD.

J Exp Med. 2016 Aug 22;213(9):1695-703. doi: 10.1084/jem.20160312. Epub 2016 Aug 8.

15.

Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis.

Villadangos JA.

Immunol Rev. 2016 Jul;272(1):169-82. doi: 10.1111/imr.12433. Review.

PMID:
27319350
16.

The intracellular pathway for the presentation of vitamin B-related antigens by the antigen-presenting molecule MR1.

McWilliam HE, Eckle SB, Theodossis A, Liu L, Chen Z, Wubben JM, Fairlie DP, Strugnell RA, Mintern JD, McCluskey J, Rossjohn J, Villadangos JA.

Nat Immunol. 2016 May;17(5):531-7. doi: 10.1038/ni.3416. Epub 2016 Apr 4.

PMID:
27043408
17.

Target Density, Not Affinity or Avidity of Antigen Recognition, Determines Adoptive T Cell Therapy Outcomes in a Mouse Lymphoma Model.

Segal G, Prato S, Zehn D, Mintern JD, Villadangos JA.

J Immunol. 2016 May 1;196(9):3935-42. doi: 10.4049/jimmunol.1502187. Epub 2016 Apr 1.

18.

Dendritic Cell Migration and Antigen Presentation Are Coordinated by the Opposing Functions of the Tetraspanins CD82 and CD37.

Jones EL, Wee JL, Demaria MC, Blakeley J, Ho PK, Vega-Ramos J, Villadangos JA, van Spriel AB, Hickey MJ, Hämmerling GJ, Wright MD.

J Immunol. 2016 Feb 1;196(3):978-87. doi: 10.4049/jimmunol.1500357. Epub 2016 Jan 4.

19.

Respiratory DC Use IFITM3 to Avoid Direct Viral Infection and Safeguard Virus-Specific CD8+ T Cell Priming.

Infusini G, Smith JM, Yuan H, Pizzolla A, Ng WC, Londrigan SL, Haque A, Reading PC, Villadangos JA, Wakim LM.

PLoS One. 2015 Nov 23;10(11):e0143539. doi: 10.1371/journal.pone.0143539. eCollection 2015.

20.

Introducing this special issue.

van Kooten C, Villadangos JA.

Mol Immunol. 2015 Nov;68(1):1. doi: 10.1016/j.molimm.2015.09.009. No abstract available.

PMID:
26597197
21.

Endogenous Murine BST-2/Tetherin Is Not a Major Restriction Factor of Influenza A Virus Infection.

Londrigan SL, Tate MD, Job ER, Moffat JM, Wakim LM, Gonelli CA, Purcell DF, Brooks AG, Villadangos JA, Reading PC, Mintern JD.

PLoS One. 2015 Nov 13;10(11):e0142925. doi: 10.1371/journal.pone.0142925. eCollection 2015.

22.

Antigen-presenting cells look within during influenza infection.

Mintern JD, Villadangos JA.

Nat Med. 2015 Oct;21(10):1123-5. doi: 10.1038/nm.3971. No abstract available.

PMID:
26444634
23.

The role of dendritic cell alterations in susceptibility to hospital-acquired infections during critical-illness related immunosuppression.

Roquilly A, Villadangos JA.

Mol Immunol. 2015 Dec;68(2 Pt A):120-3. doi: 10.1016/j.molimm.2015.06.030. Epub 2015 Aug 8. Review.

PMID:
26260212
24.

Differential use of autophagy by primary dendritic cells specialized in cross-presentation.

Mintern JD, Macri C, Chin WJ, Panozza SE, Segura E, Patterson NL, Zeller P, Bourges D, Bedoui S, McMillan PJ, Idris A, Nowell CJ, Brown A, Radford KJ, Johnston AP, Villadangos JA.

Autophagy. 2015;11(6):906-17. doi: 10.1080/15548627.2015.1045178.

25.

Criteria for dendritic cell receptor selection for efficient antibody-targeted vaccination.

Reuter A, Panozza SE, Macri C, Dumont C, Li J, Liu H, Segura E, Vega-Ramos J, Gupta N, Caminschi I, Villadangos JA, Johnston AP, Mintern JD.

J Immunol. 2015 Mar 15;194(6):2696-705. doi: 10.4049/jimmunol.1402535. Epub 2015 Feb 4.

26.

MR1 presentation of vitamin B-based metabolite ligands.

McWilliam HE, Birkinshaw RW, Villadangos JA, McCluskey J, Rossjohn J.

Curr Opin Immunol. 2015 Jun;34:28-34. doi: 10.1016/j.coi.2014.12.004. Epub 2015 Jan 17. Review.

PMID:
25603223
27.

Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8 T cells that are highly protective against influenza virus infection.

Wakim LM, Smith J, Caminschi I, Lahoud MH, Villadangos JA.

Mucosal Immunol. 2015 Sep;8(5):1060-71. doi: 10.1038/mi.2014.133. Epub 2015 Jan 14.

PMID:
25586557
28.

Modulation of antigen presentation by intracellular trafficking.

Mintern JD, Macri C, Villadangos JA.

Curr Opin Immunol. 2015 Jun;34:16-21. doi: 10.1016/j.coi.2014.12.006. Epub 2015 Jan 9. Review.

PMID:
25578446
29.

Inflammation conditions mature dendritic cells to retain the capacity to present new antigens but with altered cytokine secretion function.

Vega-Ramos J, Roquilly A, Zhan Y, Young LJ, Mintern JD, Villadangos JA.

J Immunol. 2014 Oct 15;193(8):3851-9. doi: 10.4049/jimmunol.1303215. Epub 2014 Sep 8.

30.

Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals.

Vega-Ramos J, Roquilly A, Asehnoune K, Villadangos JA.

Curr Opin Pharmacol. 2014 Aug;17:64-70. doi: 10.1016/j.coph.2014.07.013. Epub 2014 Aug 13. Review.

PMID:
25128781
31.

A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells.

Eckle SB, Birkinshaw RW, Kostenko L, Corbett AJ, McWilliam HE, Reantragoon R, Chen Z, Gherardin NA, Beddoe T, Liu L, Patel O, Meehan B, Fairlie DP, Villadangos JA, Godfrey DI, Kjer-Nielsen L, McCluskey J, Rossjohn J.

J Exp Med. 2014 Jul 28;211(8):1585-600. doi: 10.1084/jem.20140484. Epub 2014 Jul 21.

32.

Developmental regulation of synthesis and dimerization of the amyloidogenic protease inhibitor cystatin C in the hematopoietic system.

Xu Y, Lindemann P, Vega-Ramos J, Zhang JG, Villadangos JA.

J Biol Chem. 2014 Apr 4;289(14):9730-40. doi: 10.1074/jbc.M113.538041. Epub 2014 Feb 25.

33.

Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold.

Prato S, Zhan Y, Mintern JD, Villadangos JA.

J Immunol. 2013 Oct 1;191(7):3534-44. doi: 10.4049/jimmunol.1300803. Epub 2013 Sep 9.

34.

Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells.

Moffat JM, Cheong WS, Villadangos JA, Mintern JD, Netter HJ.

Vaccine. 2013 Apr 26;31(18):2310-6. doi: 10.1016/j.vaccine.2013.02.042. Epub 2013 Mar 7.

PMID:
23473776
35.

Enhanced survival of lung tissue-resident memory CD8⁺ T cells during infection with influenza virus due to selective expression of IFITM3.

Wakim LM, Gupta N, Mintern JD, Villadangos JA.

Nat Immunol. 2013 Mar;14(3):238-45. doi: 10.1038/ni.2525. Epub 2013 Jan 27.

PMID:
23354485
36.

Targeting antigen to bone marrow stromal cell-2 expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation.

Moffat JM, Segura E, Khoury G, Caminschi I, Cameron PU, Lewin SR, Villadangos JA, Mintern JD.

Eur J Immunol. 2013 Mar;43(3):595-605. doi: 10.1002/eji.201242799. Epub 2013 Feb 6.

37.

Antigen processing.

Sollid LM, Villadangos JA.

Curr Opin Immunol. 2013 Feb;25(1):71-3. doi: 10.1016/j.coi.2012.12.002. Epub 2013 Jan 1. No abstract available.

PMID:
23287556
38.

Consequences of direct and indirect activation of dendritic cells on antigen presentation: functional implications and clinical considerations.

Vega-Ramos J, Villadangos JA.

Mol Immunol. 2013 Sep;55(2):175-8. doi: 10.1016/j.molimm.2012.10.034. Epub 2012 Nov 27. Review.

PMID:
23200227
39.

Control of MHC II antigen presentation by ubiquitination.

Moffat JM, Mintern JD, Villadangos JA.

Curr Opin Immunol. 2013 Feb;25(1):109-14. doi: 10.1016/j.coi.2012.10.008. Epub 2012 Nov 24. Review.

PMID:
23183035
40.

CD69 does not affect the extent of T cell priming.

Alari-Pahissa E, Notario L, Lorente E, Vega-Ramos J, Justel A, López D, Villadangos JA, Lauzurica P.

PLoS One. 2012;7(10):e48593. doi: 10.1371/journal.pone.0048593. Epub 2012 Oct 30.

41.

DEC-205 is a cell surface receptor for CpG oligonucleotides.

Lahoud MH, Ahmet F, Zhang JG, Meuter S, Policheni AN, Kitsoulis S, Lee CN, O'Keeffe M, Sullivan LC, Brooks AG, Berry R, Rossjohn J, Mintern JD, Vega-Ramos J, Villadangos JA, Nicola NA, Nussenzweig MC, Stacey KJ, Shortman K, Heath WR, Caminschi I.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16270-5. doi: 10.1073/pnas.1208796109. Epub 2012 Sep 17.

42.

The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells.

Zhan Y, Vega-Ramos J, Carrington EM, Villadangos JA, Lew AM, Xu Y.

Eur J Immunol. 2012 Nov;42(11):2889-900. doi: 10.1002/eji.201242477. Epub 2012 Sep 3.

43.

Autophagy and mechanisms of effective immunity.

Mintern JD, Villadangos JA.

Front Immunol. 2012 Apr 4;3:60. doi: 10.3389/fimmu.2012.00060. eCollection 2012.

44.

Differential effect of CD69 targeting on bystander and antigen-specific T cell proliferation.

Alari-Pahissa E, Vega-Ramos J, Zhang JG, Castaño AR, Turley SJ, Villadangos JA, Lauzurica P.

J Leukoc Biol. 2012 Jul;92(1):145-58. doi: 10.1189/jlb.1011499. Epub 2012 Apr 27.

PMID:
22544938
45.

Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subsets.

Markey KA, Koyama M, Kuns RD, Lineburg KE, Wilson YA, Olver SD, Raffelt NC, Don AL, Varelias A, Robb RJ, Cheong M, Engwerda CR, Steptoe RJ, Ramshaw HS, Lopez AF, Vega-Ramos J, Lew AM, Villadangos JA, Hill GR, MacDonald KP.

Blood. 2012 Jun 14;119(24):5918-30. doi: 10.1182/blood-2011-12-398164. Epub 2012 Mar 13.

PMID:
22415754
46.

Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice.

Caminschi I, Vremec D, Ahmet F, Lahoud MH, Villadangos JA, Murphy KM, Heath WR, Shortman K.

Mol Immunol. 2012 Feb;50(1-2):9-17. doi: 10.1016/j.molimm.2011.11.008. Epub 2011 Dec 29.

PMID:
22209163
47.

Shutdown of immunological priming and presentation after in vivo administration of adenovirus.

Sutherland RM, Londrigan SL, Brady JL, Azher H, Carrington EM, Zhan Y, Vega-Ramos J, Villadangos JA, Lew AM.

Gene Ther. 2012 Nov;19(11):1095-100. doi: 10.1038/gt.2011.187. Epub 2011 Nov 17.

PMID:
22089496
48.

A modular and combinatorial view of the antigen cross-presentation pathway in dendritic cells.

Segura E, Villadangos JA.

Traffic. 2011 Dec;12(12):1677-85. doi: 10.1111/j.1600-0854.2011.01254.x. Epub 2011 Aug 16. Review.

49.

A critical role for granzymes in antigen cross-presentation through regulating phagocytosis of killed tumor cells.

Hoves S, Sutton VR, Haynes NM, Hawkins ED, Fernández Ruiz D, Baschuk N, Sedelies KA, Schnurr M, Stagg J, Andrews DM, Villadangos JA, Trapani JA.

J Immunol. 2011 Aug 1;187(3):1166-75. doi: 10.4049/jimmunol.1001670. Epub 2011 Jun 27.

50.

GM-CSF increases cross-presentation and CD103 expression by mouse CD8⁺ spleen dendritic cells.

Zhan Y, Carrington EM, van Nieuwenhuijze A, Bedoui S, Seah S, Xu Y, Wang N, Mintern JD, Villadangos JA, Wicks IP, Lew AM.

Eur J Immunol. 2011 Sep;41(9):2585-95. doi: 10.1002/eji.201141540. Epub 2011 Aug 4.

Supplemental Content

Loading ...
Support Center